Dactinomycin Injection is a powerful chemotherapeutic agent specifically formulated for the treatment of various malignancies including testicular cancer, Wilms' tumor, gestational trophoblastic neoplasia, and Ewing's sarcoma. This injectable formulation ensures rapid delivery of the active compound, enabling effective cytotoxic action against rapidly dividing cancer cells by intercalating DNA and inhibiting RNA synthesis. Ideal for oncologists and medical institutions specializing in cancer treatment, this product provides a critical component in multi-agent chemotherapy regimens. Manufactured under stringent quality controls, the Dactinomycin Injection offers consistent potency and sterility suitable for clinical administration.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Dactinomycin |
| Formulation | Injectable Solution |
| Indications | Treatment of testicular cancer, Wilms' tumor, gestational trophoblastic neoplasia, Ewing's sarcoma |
| Mechanism of Action | DNA intercalation and RNA synthesis inhibition |
| Administration Route | Intravenous injection |
| Packaging | Sterile vial, dosage per vial varies |
| Sterility | Sterile and preservative-free |
| Usage | Used in combination chemotherapy protocols |
| Storage Conditions | Store at controlled room temperature, protect from light |
| Attributes | Description |
|---|---|
| Concentration | Typically 0.5 mg/mL or as specified by manufacturer |
| Dosage Form | Injection |
| Volume per vial | Variable - commonly 1 mL or 2 mL vials |
| Shelf Life | Refer to manufacturer label, generally 2-3 years |
| Manufacturer Compliance | Manufactured under GMP conditions |
| Storage Temperature | 15°C to 30°C |
| Pediatric Use | Dosage and usage under specialist supervision |
| Color | Clear to slightly yellow solution |
| pH Range | Approximately 4.5 to 6.5 |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Dactinomycin Injection is specifically indicated for treatment of testicular cancer, Wilms' tumor, gestational trophoblastic neoplasia, and Ewing's sarcoma.
It is administered via intravenous injection under strict medical supervision, often as part of combination chemotherapy protocols.
Yes, the injection must be stored at controlled room temperature, between 15°C to 30°C, and protected from light to maintain its stability and efficacy.
Dactinomycin Injection can be used in pediatric cancer cases like Wilms' tumor but dosage and administration must be closely monitored by oncology specialists.
Yes, Dactinomycin Injection requires special certification such as a valid manufacturing license and compliance with CDSCO and GMP standards to be listed legally on the marketplace.
The product is manufactured under GMP conditions with strict sterility testing, accurate dosage formulation, and expiry labeling to guarantee safety and potency.
Dactinomycin is used in the treatment of testicular cancer, Wilms' tumor, gestational trophoblastic neoplasia and Ewing's sarcoma.
